Search Results - "Molecular cancer therapeutics"

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers by Goodman, Aaron M, Kato, Shumei, Bazhenova, Lyudmila, Patel, Sandip P, Frampton, Garrett M, Miller, Vincent, Stephens, Philip J, Daniels, Gregory A, Kurzrock, Razelle

“…Immunotherapy induces durable responses in a subset of patients with cancer. High tumor mutational burden (TMB) may be a response biomarker for PD-1/PD-L1…”
Get full text

Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes by Winer, Arthur, Adams, Sylvia, Mignatti, Paolo

“…The matrix metalloproteinases (MMP) are a family of proteolytic enzymes that degrade multiple components of the extracellular matrix. A large body of…”
Get full text

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy by Patel, Sandip Pravin, Kurzrock, Razelle

“…The resurgence of cancer immunotherapy stems from an improved understanding of the tumor microenvironment. The PD-1/PD-L1 axis is of particular interest, in…”
Get full text

Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies by Makhov, Peter, Joshi, Shreyas, Ghatalia, Pooja, Kutikov, Alexander, Uzzo, Robert G, Kolenko, Vladimir M

“…Renal cell carcinoma (RCC) is the most common form of kidney cancer. It is categorized into various subtypes, with clear cell RCC (ccRCC) representing about…”
Get full text

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells by Okajima, Daisuke, Yasuda, Satoru, Maejima, Takanori, Karibe, Tsuyoshi, Sakurai, Ken, Aida, Tetsuo, Toki, Tadashi, Yamaguchi, Junko, Kitamura, Michiko, Kamei, Reiko, Fujitani, Tomomichi, Honda, Tomoyo, Shibutani, Tomoko, Muramatsu, Sumie, Nakada, Takashi, Goto, Riki, Takahashi, Shu, Yamaguchi, Miki, Hamada, Hirofumi, Noguchi, Yutaka, Murakami, Masato, Abe, Yuki, Agatsuma, Toshinori

“…Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors and correlates with poor prognosis. We developed the novel…”
Get full text

Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes by Zhang, Lu, Riley-Gillis, Bridget, Vijay, Priyanka, Shen, Yu

“…Proteolysis-targeting chimeras (PROTAC) are bifunctional molecules that hijack endogenous E3 ubiquitin ligases to induce ubiquitination and subsequent…”
Get full text

Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2 -deficient Mesothelioma by Tang, Tracy T, Konradi, Andrei W, Feng, Ying, Peng, Xiao, Ma, Mingyue, Li, Jian, Yu, Fa-Xing, Guan, Kun-Liang, Post, Leonard

“…Mutations in the neurofibromatosis type 2 ( ) gene that limit or abrogate expression of functional Merlin are common in malignant mesothelioma. Merlin…”
Get full text

ATM Mutations in Cancer: Therapeutic Implications by Choi, Michael, Kipps, Thomas, Kurzrock, Razelle

“…Activation of checkpoint arrest and homologous DNA repair are necessary for maintenance of genomic integrity during DNA replication. Germ-line mutations of the…”
Get full text

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer by Gross, Matt I, Demo, Susan D, Dennison, Jennifer B, Chen, Lijing, Chernov-Rogan, Tania, Goyal, Bindu, Janes, Julie R, Laidig, Guy J, Lewis, Evan R, Li, Jim, Mackinnon, Andrew L, Parlati, Francesco, Rodriguez, Mirna L M, Shwonek, Peter J, Sjogren, Eric B, Stanton, Timothy F, Wang, Taotao, Yang, Jinfu, Zhao, Frances, Bennett, Mark K

“…Glutamine serves as an important source of energy and building blocks for many tumor cells. The first step in glutamine utilization is its conversion to…”
Get full text

Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models by Kulukian, Anita, Lee, Patrice, Taylor, Janelle, Rosler, Robert, de Vries, Peter, Watson, Daniel, Forero-Torres, Andres, Peterson, Scott

“…HER2 is a transmembrane tyrosine kinase receptor that mediates cell growth, differentiation, and survival. HER2 is overexpressed in approximately 20% of breast…”
Get full text

CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment by Fujiwara, Tomohiro, Yakoub, Mohamed A, Chandler, Andrew, Christ, Alexander B, Yang, Guangli, Ouerfelli, Ouathek, Rajasekhar, Vinagolu K, Yoshida, Aki, Kondo, Hiroya, Hata, Toshiaki, Tazawa, Hiroshi, Dogan, Yildirim, Moore, Malcolm A S, Fujiwara, Toshiyoshi, Ozaki, Toshifumi, Purdue, Ed, Healey, John H

“…Colony-stimulating factor 1 (CSF1) is a primary regulator of the survival, proliferation, and differentiation of monocyte/macrophage that sustains the…”
Get full text

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor by Perera, Timothy P S, Jovcheva, Eleonora, Mevellec, Laurence, Vialard, Jorge, De Lange, Desiree, Verhulst, Tinne, Paulussen, Caroline, Van De Ven, Kelly, King, Peter, Freyne, Eddy, Rees, David C, Squires, Matthew, Saxty, Gordon, Page, Martin, Murray, Christopher W, Gilissen, Ron, Ward, George, Thompson, Neil T, Newell, David R, Cheng, Na, Xie, Liang, Yang, Jennifer, Platero, Suso J, Karkera, Jayaprakash D, Moy, Christopher, Angibaud, Patrick, Laquerre, Sylvie, Lorenzi, Matthew V

“…Fibroblast growth factor (FGF) signaling plays critical roles in key biological processes ranging from embryogenesis to wound healing and has strong links to…”
Get full text

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance by Chen, Ping, Lee, Nathan V, Hu, Wenyue, Xu, Meirong, Ferre, Rose Ann, Lam, Hieu, Bergqvist, Simon, Solowiej, James, Diehl, Wade, He, You-Ai, Yu, Xiu, Nagata, Asako, VanArsdale, Todd, Murray, Brion W

“…Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biological perspective but drug development is often hindered by…”
Get full text

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib by Murai, Junko, Huang, Shar-Yin N, Renaud, Amèlie, Zhang, Yiping, Ji, Jiuping, Takeda, Shunichi, Morris, Joel, Teicher, Beverly, Doroshow, James H, Pommier, Yves

“…Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks. We recently reported that several PARP…”
Get full text

Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics by Gutteridge, Rosie Elizabeth Ann, Ndiaye, Mary Ann, Liu, Xiaoqi, Ahmad, Nihal

“…Polo-like kinase 1 (Plk1) overexpression has been shown to occur in a wide range of tumors, prompting research and development of Plk1 inhibitors as a means of…”
Get full text

MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2 by Li, Peilong, Zhang, Xin, Wang, Haiyan, Wang, Lili, Liu, Tong, Du, Lutao, Yang, Yongmei, Wang, Chuanxin

“…A major reason for oxaliplatin chemoresistance in colorectal cancer is the acquisition of epithelial-mesenchymal transition (EMT) in cancer cells. The long…”
Get full text

ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers by Skidmore, Lillian, Sakamuri, Sukumar, Knudsen, Nick A., Hewet, Amha Gebre, Milutinovic, Snezana, Barkho, Wisam, Biroc, Sandra Lyn, Kirtley, Jessica, Marsden, Robin, Storey, Kristine, Lopez, Ianina, Yu, Wayne, Fang, Shiao-Yan, Yao, Sulan, Gu, Yi, Tian, Feng

“…Abstract First-generation antibody–drug conjugates (ADC) are heterogeneous mixtures that have shown clinical benefit, but generally exhibited safety issues and…”
Get full text

The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models by Wengner, Antje M, Siemeister, Gerhard, Lücking, Ulrich, Lefranc, Julien, Wortmann, Lars, Lienau, Philip, Bader, Benjamin, Bömer, Ulf, Moosmayer, Dieter, Eberspächer, Uwe, Golfier, Sven, Schatz, Christoph A, Baumgart, Simon J, Haendler, Bernard, Lejeune, Pascale, Schlicker, Andreas, von Nussbaum, Franz, Brands, Michael, Ziegelbauer, Karl, Mumberg, Dominik

“…The DNA damage response (DDR) secures the integrity of the genome of eukaryotic cells. DDR deficiencies can promote tumorigenesis but concurrently may increase…”
Get full text

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer by Judd, Julia, Abdel Karim, Nagla, Khan, Hina, Naqash, Abdul Rafeh, Baca, Yasmine, Xiu, Joanne, VanderWalde, Ari M, Mamdani, Hirva, Raez, Luis E, Nagasaka, Misako, Pai, Sachin Gopalkrishna, Socinski, Mark A, Nieva, Jorge J, Kim, Chul, Wozniak, Antoinette J, Ikpeazu, Chukwuemeka, de Lima Lopes, Jr, Gilberto, Spira, Alexander I, Korn, W Michael, Kim, Edward S, Liu, Stephen V, Borghaei, Hossein

“…is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different mutations…”
Get full text

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions by Larrosa-Garcia, Maria, Baer, Maria R

“…The receptor tyrosine kinase -like tyrosine kinase 3 (FLT3), involved in regulating survival, proliferation, and differentiation of hematopoietic…”
Get full text